Archives: Published Articles

Q: Companies have made a lot of operational changes to accommodate working through the pandemic. What changes do you think will become permanent in FDA inspection procedure as a result of the pandemic?

 

A: There are a number of operational changes that companies have made to accommodate working through the pandemic. Many of the changes were implemented out of necessity. That is to say, some of the changes have the potential to become normal operating procedures. Patients still need life-saving medicines. Likewise, companies need to find ways to continue manufacturing safe, effective, and compliant products. Conducting virtual audits, virtual training, and enhancing communications with suppliers are among the changes implemented. The goal is to ensure an uninterrupted supply chain to maintain operations and stay compliant. Each of the changes have positive and negative aspects that need to be evaluated to determine if they are effective.

 

Virtual Audit Procedures

 

Moving to virtual audits was one of the first changes that was implemented by companies and regulatory authorities. The necessity for virtual audits was to allow companies and regulators to continue to evaluate the compliance stature of manufacturers while respecting stay-at-home and social distancing requirements that prevented in-person site audits.

 

There are many advantages of performing virtual audits and the key to making a virtual audit successful is preparation and communication. Informational (organizational charts, standard operating procedures, quality manual, etc.) requests should be made prior to the audit, and the requested documents should be reviewed before the commencement of the audit.

 

Documentation Procedures

 

Companies can save time and reduce travel expenditures because people will be reviewing documents from home offices. The documentation required for in-person audits will be the same as virtual audits, but rather than making copies for the auditor, the documents can be turned into a PDF file and be sent through a secure system to the requester. Questions regarding the documentation can be addressed through a number of virtual platforms as long as the platform chosen is acceptable to both parties.

 

FDA Inspection Facility Tour Procedures

 

Performing a tour of the facility poses unique challenges, and possible solutions need to be vetted between the two parties to determine the most efficient and secure way to share this information. The bottom line is that virtual audits have the potential to be as effective as in-person audits and perhaps maybe more time efficient and cost-effective.

 

FDA Inspection Virtual Training Procedures

The same principles applied to conducting virtual audits can also be applied to training. On-line training programs have been used to train remote employees for years. There are a number of technological platforms that can be used to deliver virtual training programs to employees. These platforms allow training material to be pre-recorded and comprehension questions that must be answered correctly in order to continue with the training can be inserted. Remote training allows the employee to complete the training as their schedule allows.

 

Another approach is to deliver the training as a webinar using a multiple-person meeting application. You can prepare and distribute the information you will cover in the training, schedule a meeting time, deliver the training, and take questions from the employees during the webinar. If you have multiple manufacturing shifts, you can schedule a training session during each shift to make it easier for second- and third-shift employees to receive the training.

 

Additionally, virtual training can be enhanced by taking advantage of online training and conference options offered by external organizations. Many external organizations have converted their conferences and training topics to virtual offerings covering a wide variety of topics. Some of these venues are free, and some require a registration fee.

 

FDA Inspection Supply Chain Procedures

 

Enhanced communication with suppliers to ensure an uninterrupted supply chain has also become a priority during the pandemic. Many companies are reviewing and enhancing their quality agreements. This is a positive change for the industry as a whole.

 

The quality agreement should be a living document that is reviewed and revised as often as needed to clarify the responsibilities of the client and the supplier and define how the two parties will communicate with each other. The agreement should clearly identify the roles and responsibilities needed for a successful partnership.

 

FDA Inspection Supplier Quality Procedures

 

Defining the quality relationship between a supplier and a client is complex and requires extensive discussion and attention to detail. The relationship should be open, and communication between the two parties should be as frequent as required to assure that the product being manufactured meets the highest quality standards for the client and for the patients. Bottom line is that quality agreements are important documents for ensuring the supply chain procedures during the pandemic. This is a welcome change that should carry forward in the future.

 

There are many changes that have the potential to become permanent procedures or operating principles even after the pandemic. Three that should become permanent in the future are the use of virtual audits, the implementation and utilizations of virtual training, and more robust quality agreements that enhance communications between the client and the supplier.

 

About the Publisher

 

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Q. I have heard that the International Council for Harmonization’s (ICH’s) Q9 Quality Risk Management is being revised. Do you know what the industry can expect to see with the new version of the risk management guidelines?

 

A. You have heard correctly. The guideline was first published in 2005 and, at the time of publication, it offered an overview of general quality risk management (QRM) principles including an example of a risk management lifecycle approach.

 

Risk Management Program

 

In addition, the guideline provided a list of risk tools and quality system areas critical to establishing and maintaining an effective risk management program. As stated on the ICH website, “This Guideline provides principles and examples of tools for quality risk management that can be applied to different aspects of pharmaceutical quality.

 

These aspects include development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances, drug (medicinal) products, biological and biotechnological products (including the use of raw materials, solvents, excipients, packaging and labeling materials in drug (medicinal) products, biological and biotechnological products)”.

 

Risk Management Guidelines

 

Over the past 15 years, the industry has tried to implement risk management guidelines and principles as a part of their quality management systems. The introduction to ICH Q9 states,

 

“Although there are some examples of the use of QRM in the Pharma industry today, they are limited and do not represent the full contributions that risk management has to offer”.

 

This statement still holds true today as citations for incomplete corrective action and preventive action (CAPA)/investigations typically ranks in the top five inspectional observations for the pharmaceutical and biopharmaceutical industries.

 

QRM

 

To date, QRM implementation has used simple investigational tools to solve simple problems. In addition, the industry seems to struggle with providing data or metrics to demonstrate that information from investigation results have been used to effect continuous improvement.

 

Speakers at the PDA conference also talked about some of the challenges the industry has faced in trying to implement QRM. These reasons include using QRM to justify actions instead of assessing risk and substituting risk-assessment tools for the QRM process. Other problems that seem to prevent effective implementation of QRM is using it to confirm a hypothesis or rationalize non-compliance situations.

 

ICH 9

 

Understanding the original purpose of ICH Q9 is crucial in understanding what the industry might see in terms of its revision. Current thinking, as discussed at the PDA conference, is that the EWG will focus on clarifying certain aspects of the document’s concepts in an addendum to the document. Basically, the document itself will probably not be revised but instead will be enhanced by creating a partnering document that will focus more on ‘how to do’ and less on ‘what to do’ with respect to QRM.

 

The ICH Steering Committee approved the Q9 revised concept paper in 2019, and the EWG is expected to begin working on the revision at the ICH spring meeting. A development integrated addendum according to ICH parlance means only specific sections of the guideline will be targeted for revision but a complete revision is off the table.

 

QRM System

 

It is unclear whether the ICH Q9 revision will become more of a QRM tutorial or whether it will clarify what needs to be achieved in order for a QRM system to be considered robust and effective. To accomplish the vision of making appropriate and acceptable risk-based decisions, QRM needs to be iterative and not a once-and-done exercise within the quality management system. An effective QRM system should implement a risk review program to facilitate continuous improvement efforts.

 

At a recent PDA conference, attendees were given an opportunity to tell EWG representatives what they felt needed to be added or clarified in ICH Q9. They were asked to answer the following question: If you could recommend changes to ICH Q9, Quality Risk Management, what would you recommend? The information will be provided to the EWG representatives for consideration when they begin work enhancing the document and will be posted on the PDA Letter website.

 

Some of the recommendations were as follows:

 

  • Ensure that QRM is recognized by FDA as a required quality system. Currently, the European Medicines Agency (EMA) is more likely to inspect for QRM. There should be consensus regarding more alignment between Europe and the United States on QRM.
  • Include a standardized CAPA.
  • Remove the perception that QRM is not enforced and not part of the quality system.
  • Include language that drives a holistic systems approach.
  • Provide examples or a case study featuring a QRM tool.
  • Expand clarity on the training and documentation needed for applying QRM.
  • Clarify difference between risk evaluation and risk control.
  • Define roles, particularly decision-maker roles.
  • Provide more guidance on risk acceptance.
  • Provide additional examples such as how to apply QRM to legacy products.
  • Include examples of communication flow.
  • Clarify levels of maturity for QRM in enterprise risk management.
  • Offer strategies for demonstrating QRM compliance to regulators.
  • Recommend how to prioritize compliance versus patient safety concerns.

 

Continuous Improvement

 

Bottom line, ICH Q9 is scheduled to be revised, but the risk management guidelines to be revised have yet to be identified. There is no timeline available for completion of the revision. Industry has provided feedback to representatives of the EWG on some of their thoughts on what needs to be clarified so that implementation of an effective QRM program can be achieved, and the industry can drive toward continuous improvement realizing what Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, described as:

 

“A maximally efficient, agile, flexible, pharmaceutical manufacturing sector that reliably produces high quality drug products without extensive regulatory oversight”.

 

Article Details

 

regulatory compliance

 

Pharmaceutical Technology
Vol. 44, No. 2
Pages: 58, 57

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Getting the most value out of Mergers or Acquisitions requires proper upfront legwork, risk management and risk assessment.

 

risk managementIn the business press, discussions of mergers and acquisitions (M&As) invariably include percentages of deals that did not create their expected value. Failure numbers, ranging from 60–80%, are surprisingly high. Many companies seem to pursue mergers or acquisitions without a clear picture of their potential risks. A due-diligence process that’s too high-level or superficial is often to blame.

 

For example, when a life-science company considers a merger or acquisition, the due-diligence team typically looks for 483s, Warning Letters, notified-body findings, and product recalls to find any signs of potential problems with FDA. But when a deal does not deliver value, the real causes are often strategic, cultural, or technical.

 

Risk Assessment

 

Due diligence is not the same as risk management or conducting a quality assurance compliance audit. But in the life-science industry, it’s easy to confuse the two. The executives or the private-equity firm structuring the deal do not necessarily understand the companies’ operations or FDA sanctions.

 

At the same time, if a CEO or CFO is enamored with M&As as a perceived means to expand into a new business or enter a new market, the due-diligence team typically lacks the business expertise to ask the right questions or the clout to raise objections.

 

Risk Assessment Example

 

For example, Company A might want to buy Company B because of its superior sales force. Company A’s marketing department contends that sales would double; the finance department believes that redundancy would allow Company A to reduce payroll by 10%.

 

Both predictions are correct, but no one calculates the extra manufacturing capacity needed to produce a larger portfolio and volume of products. The expected value of the deal could be canceled out by unanticipated costs in another part of the organization.

 

Level of Compliance

 

The fundamental questions asked during due diligence should go beyond FDA compliance and tackle the business reasons for closing the deal. This approach requires having the right people (not necessarily those who happen to be available) on the due-diligence team.

 

Technical executives might be asked about open citations, but they’re rarely consulted about the likely costs of integrating factories, supply chains, or distribution centers—or whether these integrations can be done at all. But if integration costs more or takes longer than expected, customer relationships and product quality can suffer.

 

Checklists for Due Diligence

 

Often in a merger or acquisition, using a checklist to gouge the personalities of the two companies are not considered relevant. But stress and tensions can build when the cultures of two organizations are incompatible. The possible triggers of a poor “culture fit” are limitless: management style, risk tolerance, flexibility, talent, technology, and geography, to name a few.

 

Some life-science companies are risk-takers; others are conservative. Some are entrepreneurial; others are hierarchical. Some are obsessed with “zero incidents” quality; others have a “find a problem, fix a problem” management style. If the two cultures can’t be blended, the cost of a significant restructuring (including recruiting and hiring new executives) needs to be included in the M&A price tag.

 

Technology Due Diligence

 

Post-M&A integration is often the cause of extra, unplanned costs. For instance, a seller often ends up supporting sold-off processes or IT systems long after the deal is done. When this happens, the buyer can end up with a poorly managed function, and the seller can end up with disgruntled clients and extended costs. The deal’s stakeholders, each with different goals and agendas, need to talk to each other. External stakeholders can also be drawn into the due-diligence process to reduce such risks.

 

Transition services agreements (TSAs) should be drawn up carefully to protect buyers and sellers from value destruction. For the buyer, a TSA might specify that the seller’s employees will be available to talk to regulatory authorities during the integration time period. For the seller, the TSA might detail roles and responsibilities for the sold business or division. A key executive or consultant should ensure that TSAs are followed and that the buyer takes over on schedule.

 

Commercial Due Diligence

 

Any life-science company considering a merger or acquisition should consider the following five steps to ensure that its due-diligence process helps manage business risks and prevent value destruction.

 

FDA Compliance

 

Put the right people on the team. You have to be compliant with your notified bodies at any moment in time. A life-sciences company typically has multiple locations, some in other countries, as well as complex supply-and-distribution operations. The time available to understand compliance while making the deal value can be short. The due-diligence team therefore should be structured to quickly obtain real-world answers to fundamental questions.

 

This means including experts who can look at limited data and draw reasonable conclusions about areas such as: manufacturing, product portfolios, supplier relationships, IT capabilities, R&D and engineering, marketing and sales, and environmental compliance. A quality assurance specialist cannot cover all this ground alone. Perhaps most important, the team needs a senior executive who has the power to champion the right answer for the deal, even when that answer is “no.”

 

Risk Analysis Process

 

Consider the following example. A US company wanting to acquire a high-growth product line made a play for a successful company headquartered in Australia. The rewards matched the company’s objectives: revenue from sales outside the US would jump from 15 to 40%.

 

However, the risks would be just as great: registrations and patents would require global management, and the success of the venture depended on keeping the seller’s key people and infrastructure.

 

Technical Risk Assessment

 

The-due-diligence team included the COO as well as senior people from manufacturing, finance, legal, quality assurance, business development, and R&D, and an independent consultant to question assumptions. In addition to working with a virtual data room, the team spent two days interviewing seven of the seller’s top executives and one day touring the main production facility.

 

The team included a senior executive who would be in charge of the postmerger integration crucial to future revenue and earnings. Because the due-diligence team had the right people, the process contributed significantly to the immediate and long-term success of the acquisition.

 

Risk Evaluation

 

Ask the right questions. In many ways, due diligence is a detective’s game: the analysts need to look at clues (often from only partial data) and solve the mystery by defining the business case for the merger or acquisition, identifying the ways each facility or function would contribute to (or detract from) the realization of the business benefits, and pinpointing risks to processes, functions, or the enterprise. Even companies that do a lot of deals are wise to treat each one as a new and unique experience.

 

Find weak spots and define fixes. The due-diligence team needs to address areas of risk management, such as the costs and efforts required to harmonize operations, the timetable for fixing problems, and the investment needed for postmerger integration. For example, upgrading an acquired company’s enterprise resource planning system would be expensive and resource-consuming; its costs should be acknowledged.

 

Hazards Assessment

 

Use facts to negotiate. The financial decision makers want to know of any issue large enough to stop the deal. But even problems that are not dealbreakers could be used in negotiations. The due-diligence team needs to be prepared to talk to C-suite executives, bond-rating agencies, investment bankers, and the sellers about issues, potential solutions, a course of action and as its timing and estimated price tag.

 

Regulatory Compliance

 

Bring in the regulators early. The postdeal organization should inform FDA or other appropriate regulators of plans to fix recognized problems. Regulators know that M&As can create confusion and inconsistencies, and they look for them during inspections. Even if there are no risk management problems, it is a good idea for the buyer to connect with regulators to help ensure a smooth transition. Due diligence is a strategy for risk management and return on investment. When done right, it helps ensure value creation in a merger or acquisition.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Experts Steven J. Lynn, executive vice-president, Pharmaceuticals for Regulatory Compliance Associates, Inc., and Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, Inc., provide simple answers to frequently asked questions regarding FDA inspections, although many of the concepts can be applied to internal and supplier audits as well.

 

Q. What documentation should I have ready to present to the inspectors?

 

regulatory complianceA. There are a number of documents and supporting evidence that can be staged prior to an inspection whether it is in-person or is being handled remotely. The objective is to make the inspection process go smoothly for both parties.

 

At a minimum, there should be a list of all current standard operating procedures (SOPs) provided to the auditor so they can choose the specific ones they are interested in reviewing, a listing of customer complaints for the past two years, a list of current closed and open deviations and corrective and preventive actions (CAPAs) for the past two years and the site’s quality manual, the current organizational charts, a copy of the employee training program, and a map of the facility. In addition, it is advisable to have a short introductory presentation (5–10 minutes) that describes the facility, the products produced, and the operating hours of the facility. This information can be provided up front for the inspectors.

 

Q. How long should an inspection/audit take?

 

A. There is really no specific time frame defined for an audit or regulatory inspections in general. Typically, supplier and internal audits should take between one to two days and a regulatory inspection typically takes three to four days.

 

Any inspection/audit can be extended depending on what the auditors/inspectors observe during the inspection. If things go well, the inspection will be completed quickly. If problems arise, the auditors may wish to extend the inspection and pursue the issue. This time frame is consistent whether the audit is done in-person or remotely.

 

Q. Do I need to make copies of everything the inspectors request?

 

regulatory compliance

A. In organizing for an inspection, it is advisable to track all audit documentation provided to the inspector. This is an important activity whether the inspection is performed in-person or remotely.

 

The inspection tends to run more smoothly when both parties are looking at and discussing the same documents. Whatever documentation is provided and kept by the inspector, it is advisable that the hosting site keep a record of the documentation.  For instance, being able to provide specific data when responding to observations associated with that documentation.

 

Basically, the hosting site needs to have an accurate log to recreate the audit activities after the inspector leaves. This is especially important when responding to the audit observation. It eliminates any questions about which document/information was discussed. Audits are fast paced, and anything that increases data integrity helps people remember what was discussed. In addition, it helps the regulatory inspections team respond to observations associated with the documentation.

 

Q. How much time do I have to answer a question after the inspector asks it?

 

A. There really isn’t a defined time frame to answer the questions. Questions that can be answered immediately should be answered immediately. Questions that need a little more investigation or clarification before answering should be responded to in a timely manner.

 

Let’s look at an example. If the inspector is reviewing a manufacturing processes technical document, they may ask to see a previous version to compare the improvement. Your QA team should know if this document is stored off site or may take time to retrieve it.

 

The delay is acceptable as long as you inform the inspector why the time is needed to provide the requested information. Bottom line, all regulatory compliance documentation should be delivered as soon as possible. If there is a delay, it is important to be transparent with the FDA inspector and explain the reason for the delay.

 

Q. If an inspector makes an observation, do I need to have a corrective action in place before the inspection ends?

 

A. No, there is no reason to have a corrective action in place before the FDA inspection ends. In some cases, the observation may be easily corrected. It can be possible to have the corrective action in place before the conclusion of the inspection. If the correction is acceptable to the inspector, this can help remove that observation from the final inspection report.

 

On the other hand, the best advice is to wait until the FDA inspection is completed before you implement any corrective action. This way you can be sure the action is appropriate for the observation. The entire team can use the time to make sure related documentation and team communication has been mass produced.

 

Article Details

 

regulatory compliance

 

Pharmaceutical Technology
Vol. 45, No. 2
Page: 58

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

Robust supplier quality agreements and good communication scheme can help avoid and alleviate regulatory concerns.

 

Managing the relationships between clients and contract manufacturing organizations (CMOs) can be difficult as the pharmaceutical landscape and its related supply chains become more global and complex. One of the best tools to achieving a good working relationship between a client and their CMO is the use of well-drafted, clear and concise quality agreements. To accomplish this, it is important to understand the different types of clients as well as the types of CMO models existing in today’s environment.

 

FDA Quality Guidance

 

In May 2013, FDA published draft guidance on quality agreements, which was finalized in November 2016 (1). Although written quality agreements are not explicitly required under existing CGMP regulations, they are required by the European regulations. Chapter 7, Outsourced Facilities, in EudraLex Volume 4 states:

 

“There must be a written Contract between the Contract Giver and the Contract Acceptor which clearly establishes the duties of each party”.

 

The FDA final guidance is titled Contract Manufacturing Arrangements for Drugs: Quality Agreements and, like all final guidances, represents FDA’s current thinking on the topic. The need for quality agreements is underscored by 21 Code of Federal Regulations (CFR) 200.10, Contract Facilities that states,

 

“Section 704(a) of the Federal Food, Drug, and Cosmetic Act specifically authorizes inspection of consulting laboratories as well as any factory, warehouse, or establishment in which prescription drugs are manufactured, processed, packed, or held”.

 

Lab Testing

 

This section of the regulations goes on to state,

 

“The Food and Drug Administration is aware that many manufacturers of pharmaceutical products utilize extramural independent contract facilities, such as testing laboratories, contract packers or labelers, and custom grinders, and regards extramural facilities as an extension of the manufacturer’s own facility.”

 

And finally, 21 CFR 211.22, Responsibilities of the Quality Control Unit, states:

 

“The quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company”.

 

The emergence of CMOs and virtual companies has been at the forefront of some of the challenges the industry is experiencing. With the finalization of the FDA guidance, it is an opportune time to revisit the concepts and ideas regarding quality agreements.

 

Quality Agreements

 

Quality agreements should not be limited to what is meant by traditional manufacturing but should be expanded to include the support activities necessary to producing a final product. It is important to put into context what is meant by “manufacturing”. For the purposes of this article, “manufacturing” will be considered anything to do with the manufacturing, testing, processing, packaging, or holding of the product including the procurement of the active ingredient, excipients, and packaging materials, including labeling, used to assemble the product.

 

Outsourced Staff

 

Another important issue to understand is the different client and CMO business models existing in the industry today. The various outsourcing models range from staff augmentation for a single activity to the full range of activities to produce the product. Partners in the contract-manufacturing niche also include the full spectrum from small to large and from early development to late-stage generic drug companies.

 

Quality Control

 

The complexity of the business models emphasizes the need of the consulting industry to employ a meaningful quality agreement. Quality control would focus on defining who is responsible for what in the relationship and what the communication scheme will be between the organization(s). 

 

Vendor Contracts and Vendor Agreements

 

Often the consistent issues within vendor contracts and vendor agreements often include the actual logistics of the agreement itself.  While there is obviously no one model for format and content, each party usually would like their own format for consistency. The real issue, however, is to agree on the scope and level of detail.

 

Manufacturing Operations

 

Looking at the situation from both sides might help in understanding the complexity of the issue. A CMO will have multiple clients. Each client will have different information they want highlighted in their quality agreements and will want to use their own quality agreement template.

 

Quality Management System (QMS)

 

Clients should look for a robust quality system and an open and communicative culture when choosing a contract organization to perform work for them. CMOs should look for clients who understand the regulations and can evaluate the CMO’s systems against those regulations rather than demanding the CMO conform to their way of doing things. Keeping track of numerous commitments can cause regulatory risk for the CMO, particularly if one client wants to have a different approach to an issue than another client. 

 

Vendor Contract Agreement

 

Let’s look at a vendor contract agreement example where robust quality agreements and a good communication scheme would have helped avoid and alleviate a regulatory concern. Keep in mind that the contracted parties involved in this scenario are unaware of the multiple contracts negotiated by the client, none of the contracts specify which party is responsible for investigations, and there is no mention in the quality agreement about how the parties will communicate in the event of an issue.

 

Clinical Manufacturing

 

The CMO was manufacturing clinical-trial materials for a client. The CMO was scheduled to perform the sixth manufacturing run of the clinical material when they noticed a different physical appearance to the API during incoming inspection.

 

The Certificate of Analysis accompanying the API indicated the material met the necessary specifications. The CMO was only capable of performing an incoming identity test because the client had contracted for the API release testing to be performed by a contract test laboratory (CTO).

 

Supplier Quality Agreement

 

The CMO contacted the client and expressed their concerns with the appearance of the incoming API. The client said that they were not concerned with the physical appearance of the API and told the CMO to manufacture the clinical-trial material. Once the manufacturing run was completed, the CMO, per the supplier quality agreement, sent the final product to a different CTO. The product failed final product release testing, and the CTO opened an out-of-specification investigation.

 

Scientific Services

 

The CTO found no error attributable to the laboratory. They contacted the client and discussed the scientific services team thought there was a problem with the manufacturing run. The client contacted the CMO and told them to investigate the incident at their facility only.

 

During the investigation, the CMO documented that they felt the failure of the product to pass the final product testing was due to the unusual appearance of the API and requested permission from the client to talk with the API manufacturer. The client denied the request; the clinical trial batch was placed on hold by the CMO; and the investigation was never closed out.

 

Quality Assurance Agreement

 

During a regulatory inspection, the inspector wanted to know what the outcome of the investigation was. The CMO had to tell the inspector that they could not complete the overdue investigation included in the quality assurance agreement because they were unable to talk to the API manufacturer. The client had told them that they investigated the API manufacture and could find nothing wrong with the API.

 

The CMO said the investigation was still open because the most probable root cause identified was the API, but it could not be verified. The result was that the CMO, the client, and the API manufacture were all issued FDA 483s and the product approval was delayed until the issue could be resolved.

 

Communication Plan

 

How could a more robust quality agreement and a communication plan have helped resolve the situation? There are a couple of recommendations to be made. The first is when there are multiple quality agreements involved, the client should make sure each of the parties are aware of each other through their quality agreement.

 

The client should also define that they will facilitate any communications between the various parties involved in the manufacturing including the testing laboratories, packagers, etc. In addition, the quality agreements should state who is responsible for the various activities including the facilitation and resolution of investigations.

 

Technical Quality Agreement

 

There is no right or wrong in crafting quality agreements. A good technical quality agreement will take into consideration the needs of the CMO, the client, adherence to compliance, and regulatory commitments of both parties. If both parties keep these principles in mind, they will have a great working relationship despite the quality agreement.

 

 

regulatory compliance

 

Article Details

Pharmaceutical Technology
Vol. 41, No. 3
Pages: 58-61

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].

A risk-managed approach to the global supply chain is more important than ever for life science manufacturers. The process is often easier said than done.   It has been half a decade since ISO 14971 listed the device requirements for a risk management system. Since then, manufacturers have struggled to implement this approach into the Quality Management System (QMS) and enhance supplier quality.

 

As the industry continues to be challenged with supplier quality, Regulatory Compliance Associates, Inc. (RCA) brought together four industry leaders to discuss best practices. These medical device quality leaders share their experiences in implementing risk managed supplier quality, driving superior outcomes and leading change in their organizations. 

 

The roundtable participants include Matt Anderson, vice president, North America quality for Merz Inc., Angel Estrada, vice president of quality and regulatory affairs for Zimmer Surgical, and Mark Iwicki, an independent consultant in life science supplier quality. The discussion is moderated by Mike Miller, director of program management for RCA

 

Miller: What is changing in supplier quality?

 

Estrada: Supplier quality is becoming more complex. We have all seen the globalization of the supply chain and the growth of outsourcing. For many of us, supplier quality used to mean managing raw components and now it can mean managing outsourced finished goods. Some suppliers own the entire production process and the device manufacturers are merely distributors who supply their label.

 

We used to focus on supplier qualification, incoming inspections and certifications of compliance. Now, with the vertical integration of suppliers, supplier quality has become much more complex and more regulated. FDA now requires registration of Tier 1 suppliers.

 

Miller: How are device manufacturers responding to the challenges?

 

Anderson: A few years back when supply chain contamination within pharmaceuticals was making front-page news, life science quality organizations focused on the GMP elements such as audits, quality agreements, and incoming inspections. These are all good things but they did not always make a huge impact on the quality coming in the door.

 

Today, many manufacturers are using more of a risk-managed approach to supplier quality. This approach addresses each supplier situation individually by evaluating the areas of greatest risk to the manufacturer, developing plans to mitigate this risk and focusing on areas that provide the greatest bang for the buck.

 

Miller: How do you see risk management playing out in your supply chain organizations?

 

Anderson: Many companies with a large supplier base are focused on compliance and trying to take care of everything. This results in diluting resources and missing what is most important. For example, many individuals felt the entire supply chain should be audited. For a large company to audit the entire vendor base, it could mean doing 50,000 to 70,000 audits per year, with each costing $5,000 and taking an entire man-day. That is not realistic. A risk-based approach to supplier quality adds value because you focus on efforts where risk is greatest.

 

You also have to incorporate business risk as well as compliance. Today that could mean ensuring continuity of materials, environmental issues, and child safety concerns versus a straight GMP compliance lens. Each organization needs to define its risk drivers and levels in order to develop a corresponding program to mitigate those risks.

 

Miller: How do you prioritize risks? How does this theory play out in practice?

 

Iwicki: RCA sponsored a paper (http://bit.ly/SJ8u8p) on the topic of risk management within the global supply chain featured in Pharmaceutical Technology. This paper outlined a prioritization schema for typical GMP elements such as patient risk, volume of product manufactured, quality data like complaints and supplier history. Combined with supplier FMEA (Failure Mode Effects Analysis), risk can be assessed and supplier control plans can be established.

 

In doing a business-based risk management, I also look at factors such as high risk of failure or uniqueness of the supplier. For example, earlier in my career I had a sole supplier for whom we could not identify a back-up alternative. With this high risk, we escalated the control plan for this supplier.

 

Miller: What can we learn from other industries?

 

Anderson: It is no secret that the automotive and aerospace industries are further along the supplier quality learning curve than the life science industry. This is due, in part, to necessity. These industries have been challenged by eroding margins and the unsustainable cost of poor quality.

 

In particular the automotive industry has raised the bar so that manufacturers partner with their suppliers to drive both greater efficiencies and higher quality. They have largely accomplished this by focusing on technical variation and true process capability within the supply chain.

 

Miller: How does this work in life science?

 

Anderson: Manufacturers need to understand their key supplier’s processes, what is critical to quality and ensures a good process capability. It means thinking of your key supplier as an extension of your own manufacturing process.

 

Iwicki: It starts with supplier qualification. In the past, we looked at this as a process in which engineering and purchasing screened suppliers, handing a short list off to quality engineering and supplier quality for approval. This can lead to suboptimal quality. The better approach is to include quality engineering and supplier quality upfront in vendor selection.

 

Anderson: As you are evaluating the supplier manufacturing process, you need to bring in technical knowledge as well as a review of the quality system. Truly partnering with your supplier means you understand their process just like you would understand your own.

 

Estrada: Essentially you are overseeing the supplier’s quality management system not just managing a supplier.
Anderson: We had an example with batteries that were passing our incoming voltage acceptance tests but were experiencing some product failures post market. When our engineer was working with the supplier, he noticed that storage temperatures were exceeding 120 degrees, which is known to shorten battery life. This may not have been detected in a typical GMP audit.

 

Estrada: Our industry tends to do a good job on the mechanics of quality such as risk management, FMEA, fault tree analysis, but we see problems in the handoffs.

 

Iwicki: One common problem in handoffs is clear communication of final specification requirements to the supplier. The manufacturer and supplier typically have early conversations. The supplier may not see the final requirements specification in print until just before they are asked to produce actual production volumes. This can uncover tolerances that are too tight for large-scale production. Since the supplier has already invested time and effort and does not want to lose the manufacturer’s business, they may agree to the requirements and figure out later how to actually meet them.

 

Estrada: All too often the yield rate is low because the manufacturing transfer is not critically examined until deviations are experienced in the first supplier run.

 

Iwicki: I see growing importance of process control with variable measurement data so you can see when something is starting to deteriorate. It is much more efficient than acceptance sampling which only tells you if there’s a catastrophic failure on hand.

 

The evaluation process of a new supplier needs to go beyond the initial approval of the supplier at a point in time, and as requirements change, a candid reappraisal must occur on both sides before approval is given for full production volumes. Adding to Matt Anderson’s statement about the supplier’s manufacturing process being an extension of the manufacturer’s, the same is true about the manufacturer’s design control process and its extension to key suppliers.

 

Estrada: To sum it up, the cross functional team on the manufacturer’s side and the suppliers need to be talking early and throughout the project to avoid these handoff issues. Early investment in the supplier relationship can pay dividends in averting future potential problems.

 

Miller: How does this shift to supplier partnering impact your culture?

 

Anderson: Establishing deep relationships with suppliers significantly alters the business climate. Now we work together on shared goals. In the past, our focus on audits and quality agreements were not real friendly to suppliers. They did not build the relationship. Rather we tend to use quality agreements as a legal document to punish when the supplier made a mistake.

 

Iwicki: I see organizations placing more importance on sustaining supplier relationships over time. It is so much easier to continually improve quality with a trusted supplier than continually seek and onboard new suppliers.

 

As personnel changes out on both sides of the manufacturer and supplier, the replacement staff needs to understand the culture and respect the prior relationships. The culture should be about quality above cost, not cost above quality.

 

Miller: How do you instill a culture of cross-functional teamwork?

 

Estrada: This is a leadership issue and must come from the top. Quality is a team sport, and everyone at Zimmer understands that. As functional leaders we lead by example and our departments understand we all play on the same team.

 

Cross-functional training and exposure builds on this foundation. Our trainers are subject matter experts (SMEs) , so they have immediate respect with the trainees. When you do not have SMEs, you take early adopters and train them to be trainers.

 

Another best practice we have seen in the military is co-location. Pilots and servicemen work in the same environment. I saw this work well at Abbott Diagnostics where quality, R&D, and quality engineering were co-located. They did a remarkable job with design transfer into manufacturing. Maybe it is because communication is in real-time and the team meets more informally. With work teams located all around the globe, we have seen SharePoint and other collaboration tools bring cross-functional areas together.

 

Miller: How does this impact your staffing considerations?

 

Iwicki: Experience matters. The supplier quality area is attracting more tenured personnel instead of being known as the jump-off point for new hires. The focus is on people who understand the true supplier quality instead of trying to get a feather in their cap for nitpicking the suppliers. I see many organizations pair up the new hires with experienced staff.

 

Estrada: We seek cross-functional team players and continue to cross-train. For example, the purchasing personnel are trained by the quality organization in the areas of GMP, change control, obsolescence and areas for the elevation of issues. Our purchasing team has become more “big picture” in their thinking. It is not just about the pursuit of a low price; It is about cost, quality and delivery.

 

About the Experts

 

Mike Miller is Director Program Management at Regulatory Compliance Associates, Inc. (RCA) and is the moderator of this paper. He is a senior quality management professional with over 25 years in the medical device industry. Before RCA, Mike held a variety of quality roles at Baxter and The General Services Administration (GSA), an independent agency of the United States government, established in 1949 to help manage and support the functioning of federal agencies. 

 

Matt Anderson is the VP, Quality Operations at Merz Aesthetics Inc. He has over twenty years of experience in quality management in the pharmaceutical industry with a focus on global supplier quality. Before Merz, he held a variety of senior Quality roles at both Baxter and Hospira. 

 

Angel Estrada, PhD is the VP of Quality and Regulatory Affairs at Zimmer Surgical. He has over twenty years of experience in quality management, starting his career in the automotive industry before transferring to medical devices. In addition to quality management, his roles include compliance and regulatory affairs. Before Zimmer, he held senior positions at Hospira, Kimberly-Clark Healthcare, Covidien, Abbott and Baxter. 

 

Mark Iwicki is a Senior Consultant at Avarent, LLC. His background includes 25 years as a quality professional in medical device and pharmaceutical manufacturing corporations. He has a strong technical background in the development and remediation of quality systems at both the direct product line manufacturing and business unit overview levels. Previously Mark was Director of Quality at Baxter.

 

To begin the Regulatory Compliance Associates scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. You may also email us at [email protected].